Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Shire in
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Shire' s performance against key rivals in the ethical
pharmaceutical sector
- See how Shire' s future performance depends heavily on its ability to
switch patients from Adderall XR to its new ADHD drugs, primarily Vyvanse
- Learn how Shire has streamlined its business to focus on specialist
therapy areas, reducing the reliance on both ADHD and the US market
View Cart
